Seminars in arthritis and rheumatismHumansMaleFemaleIndolesMiddle Aged
Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort.
Koji Suzuki, Mitsuhiro Akiyama, Kanako Shimanuki, Hiroyuki Fukui, Yuko Kaneko
Published: 202610.1016/j.semarthrit.2025.152891
Abstract
OBJECTIVE: To clarify the real-world effectiveness of nintedanib continuation beyond 12 months on pulmonary function in progressive pulmonary fibrosis (PPF) associated with systemic autoimmune rheumatic disease-related interstitial lung disease (SARD…
Preview only. Read the full abstract at the source